Department of Pathology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China.
Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Dongfeng East Road 651, Guangzhou, 510060, Guangdong, People's Republic of China.
BMC Gastroenterol. 2022 Jan 3;22(1):1. doi: 10.1186/s12876-021-02073-0.
Because of dismal prognosis in gastric cancer, identifying relevant prognostic factors is necessary. Phosphoserine phosphatase (PSPH) exhibits different expression patterns in many cancers and has been reported to affect the prognosis of patients with cancer. In this study, we examined the prognostic role of metabolic gene PSPH in gastric cancer based on the TCGA dataset and our hospital-based cohort cases.
We collected and analysed RNA-seq data of Pan-cancer and gastric cancer in the TCGA dataset and PSPH expression data obtained from immunohistochemical analysis of 243 patients with gastric cancer from Sun Yat-sen University cancer center. Further, Kaplan-Meier survival analysis and Cox analysis were used to assess the effect of PSPH on prognosis. The ESTIMATE and Cibersort algorithms were used to elucidate the relationship between PSPH and the abundance of immune cells using the TCGA dataset.
We observed that PSPH expression displayed considerably high in gastric cancer and it was significantly associated with inferior prognosis (P = 0.043). Surprisingly, there was a significant relationship between lower immune scores and high expression of PSPH (P < 0.05). Furthermore, patients with a low amount of immune cells exhibited poor prognosis (P = 0.046). The expression of PSPH significantly increased in activated memory CD4 T cells, resting NK cells and M0 macrophages (P = 0.037, < 0.001, and 0.005, respectively).
This study highlighted that PSPH influences the prognosis of patients with gastric cancer, and this is associated with the infiltration of tumour immune cells, indicating that PSPH may be a new immune-related target for treating gastric cancer.
由于胃癌预后不佳，因此有必要确定相关的预后因素。磷酸丝氨酸磷酸酶（PSPH）在许多癌症中表现出不同的表达模式，并且已有报道称其影响癌症患者的预后。在这项研究中，我们根据 TCGA 数据集和我们医院的队列病例，检查了代谢基因 PSPH 在胃癌中的预后作用。
我们收集并分析了 TCGA 数据集的泛癌和胃癌的 RNA-seq 数据，以及中山大学肿瘤中心 243 例胃癌患者免疫组化分析获得的 PSPH 表达数据。进一步，我们使用 Kaplan-Meier 生存分析和 Cox 分析评估 PSPH 对预后的影响。使用 TCGA 数据集，ESTIMATE 和 Cibersort 算法阐明了 PSPH 与免疫细胞丰度之间的关系。
我们观察到 PSPH 在胃癌中表达水平较高，并且与预后不良显著相关（P=0.043）。令人惊讶的是，PSPH 表达较高与较低的免疫评分之间存在显著关系（P<0.05）。此外，免疫细胞数量较少的患者预后较差（P=0.046）。PSPH 在活化的记忆 CD4 T 细胞、静止的 NK 细胞和 M0 巨噬细胞中的表达显著增加（P=0.037、<0.001 和 0.005，分别）。
这项研究强调了 PSPH 影响胃癌患者的预后，这与肿瘤免疫细胞浸润有关，表明 PSPH 可能是治疗胃癌的新的免疫相关靶点。
